Oral histone deacetylase inhibitor ST7612AA1 effect on diffuse large B-cell lymphoma in vitro models
Summary:
Analysis of lymphoma cell lines DOHH2 (derived from GCB-DLBCL) and TMD8 (derived from ABC-DLBCL) exposed to ST7612AA1 (300nM) for 8 hrs. ST7612AA1 is an oral thiol-based histone deacetylase inhibitor (HDACi). Results provide insight into the molecular mechanisms underlying ST7612AA1 action in DLBCL.
Vesci L, Bernasconi E, Milazzo FM, De Santis R et al. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget 2015 Mar 20;6(8):5735-48. PMID: 25671299